VTWO - Vanguard Russell 2000 ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
123.06
+0.48 (+0.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close122.58
Open122.20
Bid115.53 x 500
Ask123.54 x 500
Day's Range122.20 - 123.73
52 Week Range106.26 - 128.82
Volume41,481
Avg. Volume94,842
Net Assets2.12B
NAV125.49
PE Ratio (TTM)N/A
Yield1.15%
YTD Return2.68%
Beta (3y)1.06
Expense Ratio (net)0.15%
Inception Date2010-09-20
Trade prices are not sourced from all markets
  • Where Atara Biotherapeutics Stands This January: Analyst Ratings
    Market Realist18 days ago

    Where Atara Biotherapeutics Stands This January: Analyst Ratings

    Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.

  • Does Accelerate Diagnostics’ Financial Performance Bode Well?
    Market Realistlast month

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.

  • Market Realist7 months ago

    Decoding the Advisory Board’s Net Profit Margins in 2017

    In 1Q17, the Advisory Board (ABCO) reported adjusted EBITDA of ~$45 million, which was higher than its guidance of $37 million–$42 million.

  • Which Of These June Winners Show Strength Amid Market Weakness?
    Investor's Business Daily8 months ago

    Which Of These June Winners Show Strength Amid Market Weakness?

    A large-cap blend ETF led U.S. diversified funds in June, but small-cap names dominated the rest of the list.

  • ETF.com8 months ago

    How Russell Index Changes Impact ETFs

    Global index provider FTSE Russell just completed its annual reconstitution of key Russell indices, adjusting their mix to reflect changes in companies’ size as determined by market capitalization as well as style fit over the previous year.

  • Zacks8 months ago

    Here's Why JCPenney, Yelp, and Others Were Removed From the Russell 1000

    Major companies are set to be pushed out of the Russell 1000 Index Friday as the Russell Investment Group evaluates what companies have a high enough market cap to be a part of the index's rank.

  • Harvest Exchange10 months ago

    Chuck Royce: What's Next for Small-Caps

    Francis Gannon: Chuck, we saw major reversals in the market in 2016, really the rotation from growth to value. That changed in the first quarter of this year, where growth outperformed value. Do you think the major reversal that we saw, the value ...